acquisition Bullish 8

Merck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff

· 3 min read · Verified by 2 sources · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline.
  • The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.

Mentioned

Merck company MRK Terns Pharmaceuticals company Keytruda product TERN-701 technology Novartis company NVS

Key Intelligence

Key Facts

  1. 1Merck is acquiring Terns Pharmaceuticals for $6.7 billion in an all-cash deal.
  2. 2The acquisition price is set at $53 per share, representing a significant market premium.
  3. 3The deal is primarily driven by the need to offset revenue losses from Keytruda's 2028 patent expiration.
  4. 4Terns' lead asset, TERN-701, is a leukemia drug targeting the allosteric BCR-ABL site.
  5. 5The acquisition allows Merck to compete directly with Novartis' Scemblix in the CML market.

Who's Affected

Merck
companyPositive
Terns Pharmaceuticals
companyPositive
Novartis
companyNegative

Analysis

Merck’s $6.7 billion acquisition of Terns Pharmaceuticals represents a decisive attempt to navigate one of the most significant revenue challenges in the pharmaceutical industry: the impending patent cliff for Keytruda. As the world’s top-selling drug, Keytruda (pembrolizumab) has been the primary engine of Merck’s growth, but the loss of exclusivity expected in 2028 threatens a substantial portion of the company’s annual revenue. By acquiring Terns, Merck is not merely adding a new asset but is strategically positioning itself within the specialized oncology market of allosteric inhibitors, a field that offers high therapeutic potential with reduced toxicity compared to traditional treatments.

The centerpiece of the acquisition is TERN-701, an investigational allosteric BCR-ABL tyrosine kinase inhibitor (TKI) currently in development for chronic myeloid leukemia (CML). Unlike traditional TKIs that bind to the ATP-binding site of the BCR-ABL protein, allosteric inhibitors like TERN-701 target the myristoyl pocket. This mechanism is designed to offer greater specificity and potentially avoid the off-target side effects and resistance patterns associated with earlier generations of leukemia drugs. This move puts Merck in direct competition with Novartis, whose drug Scemblix has already validated the commercial and clinical viability of the allosteric inhibition approach in CML.

Following the $10.8 billion acquisition of Prometheus Biosciences and the $11.5 billion purchase of Acceleron Pharma, the Terns deal highlights Merck’s preference for mid-sized biotech firms with late-stage or high-potential clinical assets.

This transaction is part of a broader, multi-year M&A spree by Merck intended to de-risk its portfolio. Following the $10.8 billion acquisition of Prometheus Biosciences and the $11.5 billion purchase of Acceleron Pharma, the Terns deal highlights Merck’s preference for mid-sized biotech firms with late-stage or high-potential clinical assets. The $53 per share cash price represents a significant premium, reflecting the high stakes of the current oncology market where established players are aggressively bidding for assets that can provide immediate pipeline depth. For Merck, the integration of Terns’ small-molecule expertise complements its existing dominance in large-molecule biologics, creating a more balanced therapeutic toolkit.

What to Watch

Beyond the immediate oncology benefits, Terns also brings metabolic programs to the table, including assets targeting NASH (non-alcoholic steatohepatitis) and obesity. While Merck’s primary focus for this deal is oncology, these metabolic candidates provide additional optionality in high-growth therapeutic areas. The pharmaceutical industry is currently witnessing a convergence of oncology and metabolic research, and Merck’s expanded footprint in both could yield long-term synergies in drug discovery and combination therapies.

Investors and analysts will be closely monitoring the clinical progression of TERN-701. The success of this acquisition hinges on the drug’s ability to demonstrate superior or non-inferior efficacy to existing CML treatments in upcoming Phase 2 and Phase 3 trials. If TERN-701 can secure a significant share of the leukemia market, it will serve as a critical pillar in Merck’s post-Keytruda era. Furthermore, the deal signals to the market that Merck remains aggressive in its pursuit of external innovation, likely indicating that more "bolt-on" acquisitions are on the horizon as the 2028 deadline approaches. The regulatory environment will also be a factor, though the complementary nature of the Terns and Merck portfolios suggests a smoother path to closing than more horizontal consolidations might face.

Timeline

Timeline

  1. Acquisition Announced

  2. Expected Closing

  3. TERN-701 Data Readout

  4. Keytruda Patent Expiry

Related Stories

acquisition

Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster Oncology Pipeline

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.

acquisition

Wellgistics Health Signs $105M LOI to Acquire Neuritek Therapeutics

Wellgistics Health Inc. has entered into a non-binding Letter of Intent to acquire Neuritek Therapeutics for $105 million. The deal marks a significant strategic pivot for Wellgistics into the high-growth neurological and psychiatric drug development sector.

acquisition

Novartis Bolsters Oncology Pipeline with $3B Synnovation Breast Cancer Deal

Novartis AG has entered into an agreement to acquire SNV4818, an experimental breast cancer drug from Synnovation Therapeutics, in a deal valued at up to $3 billion. This strategic move aims to strengthen Novartis's leadership in the oncology sector as it seeks to replenish its pipeline with high-potential targeted therapies.

acquisition

Aster DM Healthcare Secures Overwhelming Approval for QCIL Merger

Aster DM Healthcare has cleared a major regulatory hurdle as shareholders and creditors overwhelmingly approved its merger with Quality Care India Limited (QCIL). The deal is set to create one of India’s largest hospital chains, significantly expanding Aster's domestic footprint following its strategic separation from its Gulf operations.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.